ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1641

Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B

Stefanie Koristka1, Marc Cartellieri2, Claudia Arndt2, Anja Feldmann2, Irene Michalk2, Claudia C. Bippes2, Nicole Berndt2, Anne Hermsdorf2, Slava Stamova2, Biji T. Kurien3, Robert Hal Scofield4, A. Darise Farris5, Judith A. James6, Holger Bartsch7 and Michael Bachmann2, 1Carl Gustav Carus TU-Dresden, Dresden, Germany, 2Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, 3College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 5Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases and autoimmunity, T cells, T-Regulatory Cells

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology in Autoimmune Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Adoptive transfer of regulatory T cells (Tregs)  represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically relevant numbers of antigen-specific Tregs. Bispecific antibodies (bsAb) are promising tools for a target-specific redirection of polyclonal Tregs. BsAb are composed of two different antigen binding moieties facilitating the cross-linkage of two different cell types.  E.g. T cells redirected by bsAb to tumor cells result in an eradication of tumor cell as shown in various in vitro, in vivo and first clinical trials. Recently, we reported that bsAb can also be used for redirection of Tregs leading to the search of potential target structures in inflamed tissues. Many pathological immune-mediated conditions, e.g. autoimmune diseases, graft rejection or GvHD are associated with massive cell death. Recently, we established a cell culture system allowing us to unequevocally show that the nuclear autoantigen La is released from dying cells and tightly binds to neighbouring living intact cells. Therefore, we wanted to learn if La can be used as inducible surface target for redirection of subpopulations of T cells including Teff and Tregs via bsAbs.

Methods:

In order to induce cell death, cultured human cells were irradiated with UV. After irradiation human cells were cocultured with untreated murine cells. Human La released and bound to the surface of co-cultured murine cells was stained with three different anti-human La specific mabs (SW5, 5B9, 7B6). These mabs recognize well defined epitopes either in the N- (SW5, 5B9) or C-terminus (7B6) of La. Alternatively, recombinant human La was added to cultured human cells. Cell surface bound La was used for redirection of sorted Tregs via two novel bispecific anti-CD3-anti-La abs. The effects of sorted redirected Tregs on activation, cytokine release, killing efficacy, and proliferation of immune effector T cells were estimated by FACS.

Results:

Two novel fully humanized bsAb targeting La and the CD3 complex of T cells were established and their capability to redirect Teff and Tregs to surface bound La was tested. Both CD4+ and CD8+ Teff redirected to surface bound La resulted in an efficient killing of target cells while highly enriched sorted Tregs were not able to mediate cytotoxicity. In contrast, the cross-linkage of Tregs with La-decorated target cells resulted in activation of both freshly isolated and expanded human Tregs. Moreover, such bsAb-activated Tregs displayed a potent suppressive capacity and negatively influenced proliferation, expansion and cytokine production of autologous CD4+ and CD8+ Teff cells.

Conclusion:

Our results indicate that La released and tightly bound to the surface of living cells are accessible for abs and can therefore be used as inducible surface target for redirecting of T cell (sub)populations via bsAb. While redirected effector T cells mediate cell death Tregs can attenuate Teff cell-mediated inflammatory immune responses and tissue destruction and may therefore be useful for a site-specific recruitment of Tregs into inflamed tissues for the treatment of GvHD, autoimmunity or transplant rejection.


Disclosure:

S. Koristka,
None;

M. Cartellieri,
None;

C. Arndt,
None;

A. Feldmann,
None;

I. Michalk,
None;

C. C. Bippes,
None;

N. Berndt,
None;

A. Hermsdorf,
None;

S. Stamova,
None;

B. T. Kurien,
None;

R. H. Scofield,

research grants from NIH and Department of Veterans Affairs,

2,

Employed by the University of Oklahoma and Department of Veterans Affair,

3;

A. D. Farris,
None;

J. A. James,

Pfizer Inc,

2,

GSK,

5;

H. Bartsch,
None;

M. Bachmann,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bispecific-antibodies-for-redirection-of-human-regulatory-t-cells-to-surface-inducible-autoantigen-lass-b/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology